RecruitingNCT06905405

The Use of Advanced Imaging in HFpEF

Assessing the Ability to Improve the Diagnosis of Heart Failure With Preserved Ejection Fraction Using Advanced Imaging Techniques


Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Enrollment

40 participants

Start Date

Aug 5, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Heart failure with preserved ejection fraction (HFpEF) causes symptoms of breathlessness and leg swelling. It is associated with significant number of hospital admissions and could lead to the patient's death. In HFpEF, the pumping function of the heart is normal but the heart is too stiff to fill properly. The first line investigation is an ultrasound of the heart (echocardiography). A number of parameters are assessed that indicate stiffness within the heart or raised pressures within the heart. However, most of these parameters lack sensitivity which can make HFpEF difficult to diagnose. The best test is to invasively measure the pressures in the heart at rest and with exercise in a procedure called heart catheterisation. However, this is invasive and not readily available. As a result, HFpEF is significantly under diagnosed meaning many patients do not get access to disease specific treatment that may improve symptoms and quality of life. There are a number of new imaging techniques that may help us to better identify HFpEF . However, it is not currently known how to best apply them in clinical practice. In this study, the investigators will recruit patients presenting to the HF clinic at Sheffield Teaching Hospitals who have symptoms of HFpEF but whose diagnosis remains unclear after initial assessment. The impact of their symptoms will be assessed with the use of a quality of life (QoL) questionnaires and a six-minute walk test (6MWT). They will undergo advanced imaging with a specialist echocardiogram and a cardiac MRI scan. If they are found to have features of HFpEF, they will be started on disease specific treatment. All patients will be followed up after six months to see if they have any symptomatic or functional improvement. They will also undergo repeat imaging to see if there has been any change in the imaging parameters.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether people with symptoms of heart failure who do not yet meet the standard diagnostic criteria actually have an early or hidden form of heart failure (called HFpEF) — using advanced imaging and a medication trial with an SGLT2 inhibitor (a drug commonly used in diabetes and heart failure). **You may be eligible if...** - You are over 18 years old, male or female - You experience shortness of breath during physical activity - You have an elevated NT-proBNP level (a blood marker of heart stress, above 400 ng/L) while in normal heart rhythm - Your echocardiogram shows an enlarged left atrium but does not yet fully meet the criteria for diagnosed heart failure **You may NOT be eligible if...** - You have a known history of heart failure with reduced ejection fraction (HFrEF) - You have type 1 diabetes, a history of diabetic ketoacidosis, or an allergy to SGLT2 inhibitor drugs - You have atrial fibrillation - You have active chest pain (angina) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTAdvanced imaging

Cardiac MRI scan Transthoracic ECHO

DRUGSGLT-2 inhibitor

SGLT-2 inhibitor


Locations(2)

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield, South Yorkshire, United Kingdom

University of Sheffield

Sheffield, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06905405


Related Trials